Estimating the Impact of Family Planning Social Marketing Activities on Reproductive Health and Empowerment Outcomes in Chad: A Randomized Controlled Trial for the Family Planning Impact Lab
NCT07930208, Not applicable, Not yet recruiting, Guttmacher Institute
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Estimating the Impact of Family Planning Social Marketing Activities on Reproductive Health and Empowerment Outcomes in Chad: A Randomized Controlled Trial for the Family Planning Impact Lab | ClinicalTrials.gov |
| NCT number | NCT07930208 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 2,150 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Guttmacher Institute | ClinicalTrials.gov |
| Conditions | Contraceptive Behavior, Pregnancy (Unwanted), Personal Autonomy, Empowerment, Intimate Partner Violence (IPV), Child Health | ClinicalTrials.gov |
| Interventions | Social marketing activities | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Proportion of Women Using (or Whose Partner Uses) a Modern Contraceptive Method (mCPR) | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 who use, or whose partners use, a modern contraceptive method. Modern methods include: female and male sterilization, oral contraceptive pills, IUDs, implants, injectables, male or female condoms, patch/ring, emergency contraception, Lactational Amenorrhea Method (LAM), fertility awareness based methods (FABM) such as standard days method and Billings ovulation method, and other supply methods (diaphram, foam/jelly). Aggregated as a proportion at each round; between-arm effect estimated via difference-in-differences. | ClinicalTrials.gov |
| Primary | Proportion of Women Whose Contraceptive Use or Non-Use Is Concordant with Their Fertility Preferences (Preference-Aligned Fertility Management) | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 classified as preference-concordant by the Preference-Aligned Fertility Management (PFM) indicator: using contraception and wanting to be, or not using and not wanting to be (adapted from the preference-aligned fertility management indicator developed by Holt and colleagues). A pre-specified sensitivity analysis classifies women reporting any pressure on their use or non-use as discordant. | ClinicalTrials.gov |
| Secondary | Unintended Pregnancy Incidence Rate | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 who report a new pregnancy that was unwanted or mistimed since the previous round, based on pregnancy history and retrospective wantedness. | ClinicalTrials.gov |
| Secondary | Proportion of Women Who Report Making the Final Decision About Contraceptive Use Alone or Jointly With Their Partner | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 who respond "you alone" or "you and your husband/partner jointly" to the question "Who would you say makes the final decision about you using contraception?" Respondents indicating that a husband/partner, parent/caregiver, a health care provider, another family member, or another person decides alone or jointly are classified as not having decision-making autonomy. | ClinicalTrials.gov |
| Secondary | Proportion of Women Reporting That Their Contraceptive Use or Non-Use Was Entirely Their Own Choice | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of non-pregnant women aged 15-49 who respond "entirely my choice" to whether their current contraceptive status reflects their own choice, free from pressure. Current users are asked whether use of their current method was their choice ("that no one pressured you or strongly encouraged you to use this particular method"); non-users are asked whether not using is their choice ("that no one pressured you into not using"). The measure operationalizes freedom from pressure as a component of contraceptive autonomy (Senderowicz 2020) | ClinicalTrials.gov |
| Secondary | Mean Score on the Contraceptive Self-Efficacy Among Women in Sub-Saharan Africa (CSESSA) Scale | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Mean score on the validated 10-item CSESSA for women aged 15-49. The score is calculated by summing all item values, creating a total score ranging from 0 to 100 across the partner-communication, provider-communication, and choosing/managing-a-method subscales. | ClinicalTrials.gov |
| Secondary | Proportion of Women With Unmet Need for Modern Contraception | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 with an unmet need for modern contraception, following the revised DHS definition (Bradley et al. 2012). A woman has unmet need for modern contraception if she is fecund; exposed to the risk of pregnancy (i.e. currently married or in union (assumed exposed), or unmarried and sexually active in the past 30 days); wants to stop childbearing, delay the next birth by at least two years, or is undecided about timing - or is pregnant or postpartum amenorrheic following a mistimed or unwanted pregnancy - and is not using a modern contraceptive method. | ClinicalTrials.gov |
| Secondary | Proportion of Women With Supply-Side Unmet Need For Modern Methods of Contraception | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women who report supply-side unmet need for modern contraceptive methods. Supply-side unmet need classifies women with unmet need (revised DHS definition, any modern method, as above) who report at least one access-related reason for non-use, following Senderowicz and Maloney (Population and Development Review, 2022). Access-related reasons captured by the survey are: knows no method; knows no source; lack of access or distance; cost; preferred method not available; no method available. Women with unmet need who cite only demand-side reasons (e.g., opposition to use, side-effect or health concerns) constitute demand-side unmet need, the complement of supply-side unmet need among women with unmet need. A pre-specified sensitivity analysis instead restricts to women with unmet need who report wanting to use contraception (Senderowicz et al., Studies in Family Planning, 2023). | ClinicalTrials.gov |
| Secondary | 12-Month Contraceptive Discontinuation Rate | Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | The proportion of episodes of modern contraceptive method use discontinued within 12 months of initiation, estimated from the survey's month-by-month contraceptive calendar using single-decrement life-table methods, following DHS analytic conventions. We define the end of an episode at the first calendar month of non-use; a switch to another modern method in the same or immediately following month is treated as continued contraceptive use in the overall rate and as method-specific discontinuation in method-level rates. Overall and method-specific 12-month discontinuation rates will be reported, distinguishing discontinuation while still in need of contraception from discontinuation due to no need (e.g., seeking pregnancy). The calendar administered at each wave covers at least the preceding 12 months, so each assessment reflects use episodes observable in that window. | ClinicalTrials.gov |
| Secondary | Proportion of Women Reporting Physical, Emotional, Sexual, or Economic Intimate Partner Violence (IPV) | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 who report experiencing physical, emotional, sexual, or economic intimate partner violence in the past 12 months as assessed using the DHS domestic violence module | ClinicalTrials.gov |
| Secondary | Mean Score On 9-Item Women's Agency Measure | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Mean score on a nine-item self-reported measure of general agency covering decision-making over daily life, voice, capacity to act on life choices, and freedom of movement. Items were adapted from established frameworks for measuring women's and adolescent girls' agency. Each item is rated on a five-point scale from strongly agree to strongly disagree and combined into a mean score, with higher scores indicating greater agency. Administered to all women aged 15-49 at each survey wave. | ClinicalTrials.gov |
| Secondary | Mean Score on the Short 5-Item Reproductive Coercion Scale | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 reporting any of the five reproductive-coercion behaviors on the validated 5-item short-form Reproductive Coercion Scale (or the mean item count) in the past 12 months. Coercive behaviors include: being told not to use contraception; having birth control taken away or being kept from obtaining it; being made to have unprotected sex in order to become pregnant; condom removal during sex; and deliberate condom damage. Items are adapted to ask about coercion by any person, not only an intimate partner. | ClinicalTrials.gov |
| Secondary | Proportion of Respondents' Children of Who Dropped Out of School | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | At baseline, this is the proportion of respondents' youngest children over age 5 who are not currently enrolled in school, but who attended school at some point in the most recent school year. For subsequent rounds, it is the proportion of respondents' youngest children over age 5 enrolled in school at the last round who are no longer attending by current round. | ClinicalTrials.gov |
| Secondary | Proportion of Respondents' Children whose Health is the Same or Better Than Children Their Age | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of respondents' children who are reported to be in the same or better health than children their own age. This will be assessed by asking "Compared to other children of this age, would you say \[child\]'s health is: Same; Better; Worse?" | ClinicalTrials.gov |
| Secondary | Proportion of Respondents Who Report That People in Their Community Think Women Should Ask Their Husbands for Permission to Use Contraception | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of respondents' who respond "Strongly Agree" or "Agree" to the statement that most people in their community think that "Women should ask their husbands for permission to use contraception." | ClinicalTrials.gov |
| Secondary | Proportion of Respondents Who Have Heard of DKT Branded Contraceptive Products | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of respondents who respond that they have heard of at least one DKT branded contraceptive product. | ClinicalTrials.gov |
| Secondary | Proportion of Women Who Report That Cost Would Be a Barrier To Accessing a Contraceptive Method | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of women aged 15-49 who respond "completely agree" or "agree" to the statement "If I wanted to use contraception, the cost would be a barrier for me." The item is administered to all women regardless of current contraceptive use. | ClinicalTrials.gov |
| Secondary | Proportion of Female Contraceptive Users Who Are Satisfied With Their Method | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Proportion of female contraceptive users who report being satisfied or very satisfied with their method. | ClinicalTrials.gov |
| Secondary | Mean Score on the 4-Item Desire to Avoid Pregnancy Scale (DAP-4) | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Mean score on the Desire to Avoid Pregnancy Scale (DAP-4), comprising four hypothetical statements on thoughts and feelings about the idea of having a baby in the next year, with 5 scaled response categories of "strongly agree" "agree" "neither agree nor disagree" "disagree" "strongly disagree". | ClinicalTrials.gov |
| Secondary | Mean Score on 10 Items Selected From the Gender-Equitable Men (GEM) Scale | Baseline; Month 12 of intervention; Month 24 of intervention; Month 36 of intervention (Endline) | Mean score on 10 hypothetical statements from the Gender-Equitable Men (GEM) Scale, assessing support for equitable vs inequitable gender norms across several domains, with 3 scaled responses: "Agree", "Partially agree" and "Do not agree" | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)